GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Memphasys Ltd (FRA:IG7) » Definitions » Total Liabilities

Memphasys (FRA:IG7) Total Liabilities : €4.01 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Memphasys Total Liabilities?

Memphasys's Total Liabilities for the quarter that ended in Dec. 2023 was €4.01 Mil.

Memphasys's quarterly Total Liabilities increased from Dec. 2022 (€3.88 Mil) to Jun. 2023 (€4.51 Mil) but then declined from Jun. 2023 (€4.51 Mil) to Dec. 2023 (€4.01 Mil).

Memphasys's annual Total Liabilities increased from Jun. 2021 (€3.79 Mil) to Jun. 2022 (€4.31 Mil) and increased from Jun. 2022 (€4.31 Mil) to Jun. 2023 (€4.51 Mil).


Memphasys Total Liabilities Historical Data

The historical data trend for Memphasys's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Memphasys Total Liabilities Chart

Memphasys Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.95 3.79 4.31 4.51

Memphasys Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.89 4.31 3.88 4.51 4.01

Memphasys Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Memphasys's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.449+(1.062+-3.3219954564956E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.001)
=4.51

Total Liabilities=Total Assets (A: Jun. 2023 )-Total Equity (A: Jun. 2023 )
=9.086-4.575
=4.51

Memphasys's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.992+(1.015+0.0010000000000001
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=4.01

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=8.069-4.061
=4.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Memphasys Total Liabilities Related Terms

Thank you for viewing the detailed overview of Memphasys's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Memphasys (FRA:IG7) Business Description

Traded in Other Exchanges
Address
30 Richmond Road, Homebush, Sydney, NSW, AUS, 2140
Memphasys Ltd is an Australian-based emerging small-cap reproductive biotechnology company. It develops and commercializes novel reproduction and fertility solutions for humans and animals. Its technology includes Hydrogel and other polymer membrane technology development. The company is developing novel medical devices, diagnostics, and media with applications to assisted reproduction technologies, including IVF in humans and artificial insemination in animals.

Memphasys (FRA:IG7) Headlines

No Headlines